A substantive expansion of the prohibition against kickbacks to pharmacy benefit managers. v2 broadens the scope of prohibited compensation beyond mere referrals to include payments related to various contracting processes and introduces a rebuttable presumption for payments to brokers and consultants, requiring documentation of fair market value for bona fide services.
PBM Kickback Prohibition Act
- Sponsor
- Rep. Allen, Rick W. [R-GA-12]
- Committees
- Education and Workforce Committee (primary)
- Last action
- Jul 2, 2026
Bottom line
The bill aims to increase transparency and reduce conflicts of interest in PBM contracting for employer-sponsored health plans by banning certain referral fees and requiring clear documentation for other compensation.
What it actually does
This bill amends the Employee Retirement Income Security Act (ERISA) to explicitly prohibit pharmacy benefit managers (PBMs) from paying direct or indirect compensation (kickbacks) to any individual or entity for securing, retaining, or influencing the business of an ERISA-covered health plan. It establishes a strong presumption that payments from PBMs to brokers, consultants, or advisors are prohibited kickbacks unless proven to be fair market value for bona fide services through contemporaneous written documentation.
Proponents argue
Supporters argue this bill will lower healthcare costs for employers and plan participants by eliminating hidden fees and anti-competitive practices by PBMs, fostering greater transparency and fair market competition. They contend it protects plan fiduciaries from conflicts of interest and ensures PBMs act in the best interest of the plans they serve.
Opponents contend
Opponents, likely from the PBM industry and some brokerage firms, might argue that existing regulations are sufficient to ensure transparency and that the bill's broad prohibition and strong presumption could disrupt legitimate business practices, increase administrative burdens, or inadvertently reduce access to valuable advisory services without guaranteed cost savings.
The bill is very short and straightforward to read, allowing ample time for a thorough evaluation of its provisions and implications.
Section 2(a), amending Section 408(b)(2)(B) of ERISA
Prohibition on PBM Kickbacks for Covered Plans
This provision adds a new clause to ERISA, making it illegal for pharmacy benefit managers (PBMs) to pay any direct or indirect compensation to individuals or entities for referring, recommending, retaining, or renewing a covered plan's business, or for influencing any part of the contracting process, such as requests for proposals or evaluations. It clarifies that the economic substance of the payment, not just its label, determines if it's a prohibited kickback. This aims to prevent hidden payments that could sway PBM selection away from the best interests of the health plan.
Supporters argue
Supporters argue this provision is crucial for ensuring that PBMs act in the best interest of health plans and their participants, rather than being influenced by hidden payments. It promotes fair competition and transparency, which should ultimately drive down prescription drug costs by removing perverse incentives.
Critics contend
Some in the PBM industry or related brokerage firms might argue that such payments are legitimate compensation for services rendered (e.g., marketing, administrative support) and that a blanket prohibition or strong presumption could disrupt efficient market functions or increase administrative burdens without guaranteed cost savings. They might also contend that existing disclosure requirements are sufficient.
Tradeoffs
The bill aims to balance the need for transparency and fiduciary responsibility with the potential for disrupting established, albeit opaque, business models in the PBM and brokerage industries. It seeks to eliminate potentially harmful conflicts of interest while ensuring legitimate services can still be compensated appropriately, albeit with greater scrutiny.
This subclause creates a strong legal presumption that any compensation paid by a PBM to a brokerage firm, broker, consultant, advisor, or related entity is a prohibited kickback. This presumption can only be overcome if the parties demonstrate, through contemporaneous written documentation, that the compensation reflects fair market value for bona fide services actually rendered AND is not related, directly or indirectly, to any prohibited activity (like referrals or influencing contracting).
Section 2(a), subclause (III)
Why it matters:This is standard legislative practice for defining evidentiary standards and rebuttable presumptions in legal amendments. It serves as a critical enforcement mechanism, rather than being evasive.
Case for: Proponents argue this presumption is essential to make the kickback prohibition enforceable. Without it, PBMs and brokers could easily re-label prohibited payments as 'consulting fees' or 'administrative services,' undermining the intent of the law. It effectively shifts the burden of proof to those receiving and paying the compensation to demonstrate its legitimacy.
Case against: Critics might argue this creates an overly burdensome standard for legitimate business relationships, potentially stifling innovation or increasing compliance costs for brokers and PBMs. They might contend it could lead to a chilling effect on necessary advisory services for health plans.
Estimated impact: This provision significantly impacts the business models and compliance requirements for PBMs and the brokers/consultants who advise ERISA plans on PBM selection. It could lead to a restructuring of compensation arrangements in the industry.